8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2017

Medizone International, Inc.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Number) 87-0412648 (IRS Employer Identification No.)

350 East Michigan Avenue, Suite 500, Kalamazoo, MI 49007

(Address of principal executive offices, Zip Code)

Registrant’s telephone number, including area code: (269) 202-5020

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On March 1, 2017, Medizone International, Inc. (the “Company”) issued a press release announcing it had entered into an agreement with EMA Partners, LLC to provide financial advisory and investment banking services in connection with financing and commercial development, cooperation, service and distribution arrangements. Registered broker-dealer services that may be required by the agreement will be provided by Burch & Co., Inc. and its affiliates.

The Company previously announced on February 27, 2017, that it would post a document titled “Medizone International, Inc. Investor Update – March 2, 2017” (the “Investor Update”) on the Company’s website and that executives of the Company would hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provide access information, date and time for the conference call.  The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questions and answers.

A copy of the press release of March 1, 2017, and the Investor Update, are furnished herewith as Exhibits to this Current Report on Form 8-K and are incorporated herein by reference.  These documents will be posted on the Company’s corporate website, www.medizoneint.com.  

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 9.01  Financial Statements and Exhibits.

(d)  Exhibits

Exhibit Number	Description
99.1	Press Release dated March 1, 2017
99.2	Investor Update March 2, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.
By:	/s/ David A. Esposito
	David A. Esposito Chief Executive Officer

Date: March 1, 2017

EX-99.1

Exhibit 99.1

Contact: John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: j.pentony@medizoneint.com

Medizone International to Host Investor Conference Call

KALAMAZOO, MICH. March 1,2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today that the Company will host a webcast and conference call on March 2, 2017, to discuss the recent leadership transition, current priorities and its commercial strategy.

Investor Conference Call Details

Date: Thursday March 2, 2017Time: 10 AM EST

Materials for the Investor Conference Call will be made available at 4:00 PM EST on March 1, 2017.

The slides can be accessed at www.medizoneint.com

Telephone:

North American callers, dial 888 227 8942.  International callers, dial +1 303 223 4375

There is no access code required.  Simply call into the assigned phone number.

An archive of the slides will be available at www.medizoneint.com A replay of the conference call will be available from March 2 at 1:00 PM EST through March 9 at 1:00 PM EST by calling 800 633 8284. The access code for the replay is 21847605.  The slides, conference call, and replay are open to all interested parties.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 in response to the increased prevalence and awareness of hospital acquired infections.  The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the Company is now prepared to expand into the U.S. market.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: j.pentony@medizoneint.com

For more information, visit:

http://www.medizoneint.com

Email: operations@medizoneint.com

EX-99.2

Exhibit 99.2